Figure 1.

Serological response against COVID-19 vaccine in plasma of rituximab-treated patients and healthy donor before and after receiving the booster dose. (A) IgG titers in plasma from individuals with hematological disease who received rituximab before the second dose of vaccine (pre-booster) and the booster dose of SARS-CoV-2 vaccine, in comparison with healthy donors. (B) Neutralizing antibody titer at 50% inhibition (NT50) against SARS-CoV-2 of plasma isolated from individuals who received rituximab and healthy donors before and after the booster dose of COVID-19 vaccine. Each dot in the graphs corresponds to mean and the vertical lines correspond to standard error of the mean (SEM). Statistical significance within groups was calculated using the Wilcoxon signed-rank test.